Use of GP73 in the diagnosis of non-alcoholic steatohepatitis and the staging of hepatic fibrosis

• Published in: Journal of international medical research 2021-11, Vol.49 (11), p.3000605211055378
• Main Authors: Li, Yadi, Yang, Yan, Li, Yufang, Zhang, Ping, Ge, Gaiying, Jin, Jing, Du, Ting, Ma, Maiyan, Na, Li, Ding, Lu, Sheng, Huiping
• Format: Article
• Language: English
• Subjects: Alanine Transaminase; gamma-Glutamyltransferase; Humans; Liver; Liver Cirrhosis - diagnosis; Membrane Proteins - analysis; Non-alcoholic Fatty Liver Disease - diagnosis; Retrospective Clinical Research Report
• ISSN: 0300-0605; 1473-2300; 1473-2300
• DOI: 10.1177/03000605211055378

Objective To evaluate the utility of Golgi protein 73 (GP73) in the diagnosis of non-alcoholic steatohepatitis (NASH) and hepatic fibrosis (HF) staging. Methods Ninety-one patients with non-alcoholic fatty liver disease (NAFLD) were allocated to NAFL (n = 46) and NASH (n = 45) groups according to their NAFLD activity score (NAS), and there were 30 healthy controls. Serum GP73 was measured by ELISA, GP73 protein expression was evaluated using immunohistochemistry, and FibroScan was used to determine liver hardness. Results The serum GP73 concentrations of the NAFL and NASH groups were significantly higher than those of controls. GP73 expression in the liver of the patients gradually progressed from absent or low to moderate or high. Serum GP73 positively correlated with liver expression, and the serum and liver GP73 of the patients positively correlated with FibroScan value and HF stage. There was a strong positive correlation of the combination of alanine aminotransferase, gamma glutamyl transferase and GP73 with NASH. The combination of serum GP73 and FibroScan value was found to predict NASH (NAS > 4) and advanced HF (stage ≥2) in patients with NAFLD using receiver operating characteristic analysis. Conclusion Serum GP73 may be useful in the diagnosis of NASH and the staging of HF.